The Essential Role of Clinical Social Work in Oncology

News
Video

Kelly Dyckman, MSW, LCSW, discusses how her role integrates with multidisciplinary oncology teams to support patients' emotional and relational well-being.

While oncologists, surgeons, and nurses form the core of a patient’s medical support, an essential piece of the multidisciplinary care team is the clinical social worker. To shed light on this crucial role, Kelly Dyckman, MSW, LCSW, spoke with CancerNetwork®, regarding how a patient’s emotional and relational health is inextricably linked to their physical well-being and their overall response to treatment.

Dyckman’s primary focus is on the emotional landscape of the patient, providing a vital psycho-social assessment that complements the medical team’s clinical data. While a doctor is rightfully focused on treating the cancer, Dyckman is tasked with considering how that intensive treatment plan—from chemotherapy to post-operative recovery—is truly impacting the patient.

Moreover, as a clinical social worker, Dyckman offers support to the patient’s entire care team. The stress of a caregiver can often create additional guilt and anxiety for the patient, which can have downstream implications for their physical health. By supporting family members and providing them with resources, Dyckman can help to alleviate stress for the entire family unit.

Dyckman is a licensed clinical social worker at Navesink Wellness Center.

Transcript:

Being a clinical social worker can be valuable in a care team and a medical team. I am primarily focused on [a patient’s] emotional well-being, and there’s also considerations as to how emotional well-being influences physical health relationships. To have a clinical social work assessment on the patient and the patient's well-being is important. When we are talking about cancer, in particular, it’s impossible not to consider the implications of treatment, surgeries, and all the different aspects that cancer can have on that person’s individual well-being.

Obviously, the doctor is focused on addressing [and] treating the cancer, and doing the best they can to resolve the cancer situation. My responsibility is to consider how that treatment plan is impacting that [patient], emotionally, psychologically, relationally, what that looks like in their day-to-day life from a functionality perspective, because without that input, the doctor and nurses may be missing crucial cues as to what’s working, what’s not working.

In the past, when I have worked with people in a treatment setting, considering how they are responding to chemotherapy from a physical standpoint, and what that looks like emotionally, what that looks like relationally––how is the patient functioning at home? What does that look like on post-treatment? What does that look like pre-treatment? If the doctor and nurse team do not have that information, there may be steps they can offer to support that patient, to assist them in navigating it more effectively.

If anxiety spikes before chemotherapy, [a patient] may need a session with me, or somebody may benefit from psychotropic medication in support of navigating the treatment process. If a caretaker is having a difficult time, resulting in guilt and anxiety by the patient, being able to support that family member, give them additional support resources can alleviate some of the additional stress, additional anxiety that may have implications for the physical health and well-being of that patient, that if we do not have eyes on the human being, we can lose a lot in translation.

Recent Videos
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content